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Aims: Recent population-based data on drug utilization around pregnancy are lacking.
This study aims to examine the prevalence of drug exposure in the Netherlands dur-
ing the preconception, pregnancy and postpartum periods, with special emphasis on
trends of potentially harmful medication over the years.
Methods: A population-based study was conducted using records from the
PHARMO Perinatal Research Network. From 1999 to 2017, the proportion of preg-
nancies during which women used any medication or potentially harmful medication
was assessed, overall and stratified by timing of exposure relative to pregnancy and
by the year of delivery.
Results: Overall, 357 226 (73%) and 166 484 (34%) of 487 122 selected pregnancies
were exposed to any and potentially harmful medication, respectively. Among these
487 122 pregnancies, preconception prevalence for use of potentially harmful medi-
cation was 43%, 24% during the first trimester, 19% during the second, 16% during
the third, and 45% postpartum. A declining trend was observed for exposure to any
medication, from 84% in 1999 to 68% in 2017. No clear changes were observed over
time for the proportion of pregnancies exposed to potentially harmful medication.
Conclusions: Our study shows that the use of potentially harmful medication was
high over the last two decades. Although there was a declining trend over the years
in overall medication use, during a steady one-third of pregnancies, women used
potentially harmful medication. Our findings highlight the need for an increased
sense of urgency among both healthcare providers and women of reproductive age
regarding potential risks associated with pharmacological treatment during
pregnancy.
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1 | INTRODUCTION
The potentially harmful effects on the mother, embryo or fetus, and
newborn of medication used before, during and after pregnancy are
well known and can lead to major birth defects. It is therefore
undisputed that safe pharmaceutical care around pregnancy is of vital
importance. There are critical time points during a pregnancy when
medication is likely to impact pregnancy outcomes. In the first trimes-
ter, risk of spontaneous abortion and birth defects are highest
because of organogenesis. However, after the first trimester, terato-
gens can still affect development of fetal organs and tissues such as
the brain.1,2
Despite this, drug exposure during pregnancy is common in
Europe and the US.3–5 Prior drug utilization studies have revealed
an overall prescription rate of up to 79% during pregnancy in the
period 1994 to 2013 in the Netherlands.6,7 A multinational study
showed that compared to other (European) countries, prevalence
of any medication use during pregnancy was high in the Nether-
lands (95% vs. on average 81%).4 For certain chronic conditions
like epilepsy or diabetes, medical treatment cannot be easily
avoided. In case of potential teratogenicity, switching to alternative
(pharmaceutical) treatment, lowering the dose or temporary cessa-
tion should be considered. However, it remains a matter of
balancing fetal and maternal risks, especially in case of chronic
conditions.8
The public health importance of monitoring drug use around
pregnancy has been recognized from a national as well as from an EU
perspective.9,10 Recent long-term population-based data on drug utili-
zation before, during and after pregnancy in the Netherlands are lac-
king. Such data would allow for more intense future interventions
targeted at preventing use of potentially harmful medication during
pregnancy. The objective of the current study was to examine, at a
population level, the prevalence of drug exposure during the precon-
ception, pregnancy and postpartum periods in the Netherlands, with
special emphasis on potentially harmful medication, and to assess
trends over the years.
2 | METHODS
2.1 | Study design and data sources
This population-based study was performed using the PHARMO Peri-
natal Research Network (PPRN), which combines records from the
Netherlands Perinatal Registry (Perined) and the PHARMO Database
Network (PHARMO).11 Perined is a nationwide registry that contains
validated data from pregnancies with a gestational age (GA) of at least
16 weeks.12 PHARMO comprises a dynamic cohort of participants
and includes, among other information, drug-dispensing records from
community pharmacies for more than three million individuals
(approximately 25% of the Dutch population) collected since
1998.13,14 The Out-patient Pharmacy Database contains the following
information per filled prescription: the Anatomical Therapeutic
Chemical (ATC) classification of the drug, dispensing date, dose regi-
men, prescribing physician, quantity dispensed and estimated duration
of use.15 The Out-patient Pharmacy Database represents the Dutch
population that has picked up prescription drugs or has registered
with a pharmacy and has been shown to be representative of the gen-
eral Dutch population in terms of age and gender. The linkage
between PHARMO and Perined has been described in detail else-
where but was generally based on the birth date of the mother and
child and their addresses and could be established for about 20% of
the pregnancies in Perined.11,16 Women who gave birth between
1999 and 2017 were selected from the PPRN, including both live and
stillbirths (GA ≥22 weeks). No exclusion criteria were applied in order
to increase the generalizability of the results. To allow for women's
medication use to be assessed during the preconception, pregnancy
and postpartum periods, their details needed to be registered in the
Out-patient Pharmacy Database from 40 weeks before the concep-
tion date (based on ultrasound or first day of the last menstrual period
[LMP]) until 40 weeks after the delivery date as recorded in Perined.
For the current database research with anonymous data, no Institu-
tional Review Board or ethics committee approval was required.
2.2 | Drug exposure during the preconception,
pregnancy and postpartum periods
All drug dispensing records of the women in the PPRN were
selected from the Out-patient Pharmacy Database and the length of
each dispensing was calculated by dividing the total number of dis-
pensed units by the number of units to be taken per day.
What is already known about this subject
• The potentially harmful effects on the mother, embryo or
fetus, and newborn of some medication used before, dur-
ing and after pregnancy are well known.
• Despite this, drug exposure during pregnancy is common
in Europe and the US.
• Recent long-term population-based data on drug utiliza-
tion before, during and after pregnancy in the Nether-
lands are lacking.
What this study adds
• Over all the study years, potentially harmful medication
was used during a steady one-third of pregnancies.
• Our findings highlight the need for an increased sense of
urgency among both healthcare providers and women of
reproductive age regarding the potential risks associated
with pharmacological treatment during pregnancy.
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Dispensings were converted into treatment episodes of
uninterrupted use to be able to determine drug exposure over time.
Drug exposure preconception was defined as an active treatment
episode within 40 weeks before the conception date. Drug expo-
sure during pregnancy was similarly assessed from on or after the
conception date until delivery date and classified by pregnancy tri-
mester: up to the week 12 of amenorrhea (first), 13–27 weeks (sec-
ond) and 28 weeks to delivery (third). Drug exposure postpartum
was assessed during the 40 weeks after delivery. Although the con-
ventional definition of the periconceptional period is shorter, these
periods were defined in order to have time windows of similar
length and thereby allow comparability of drug exposure between
the three periods. Sensitivity analyses were performed in which
drug exposure during these periods was based on drug dispensings
rather than treatment episodes. Drug exposure to medication not
indicated as safe (hereafter referred to as “potentially harmful medi-
cation”) was classified according to Categories 2–6 of the 2016 risk
classification system for drugs in pregnancy of the Dutch Teratology
Information Service Lareb (see Table 1 and Appendix Table 1).17
Although this classification system is directed specifically at drug
use during pregnancy, the same classification was applied to the
postpartum period in order to visualize periconceptional exposure
patterns (i.e. without applying breastfeeding-specific risk
classification).
TABLE 1 Overview of medication categories according to the 2016 risk classification system for drugs in pregnancy of the DutchTeratology
Information Service Lareb
Category Label Descriptiona
1. Wide experience; can be used Medicines used in research or in practice
without showing a raised prevalence of
congenital defects, or (in)direct harmful
effects in the embryo, fetus or newborn.
This category is not taken into account
separately in the current study.
2. Pharmacological effects; require monitoring Medicines known or suspected to result in
pharmacological effects in the embryo,
fetus or newborn. The use of these
medicines must be considered carefully.
When used, monitoring for side effects is
needed.
3. Pharmacological effects; avoid (temporarily) Medicines known or suspected to result in
pharmacological effects in the embryo,
fetus or newborn. These medicines
should not be used during this hazardous
period; an alternative medicine should be
chosen.
4. Teratogenic effects; require monitoring Medicines known or suspected to cause a
higher prevalence of congenital defects
or other permanent damage or that can
have harmful pharmacological effects in
the embryo, fetus or newborn. Usage
must be considered carefully, and if so,
monitoring for undesirable effects is
needed.
5. Teratogenic effects; avoid (temporarily) Medicines known or suspected to cause a
higher prevalence of congenital defects
or other permanent damage and that can
have harmful pharmacological effects in
the embryo, fetus or infant. These
medicines should not be used during this
hazardous period; an alternative medicine
should be chosen.
6. Unknown risk Medicines of which the risk for the embryo,
fetus or newborn cannot be determined
because there are insufficient data on
their effect in humans. The use of these
medicines must be considered carefully
and, when possible, another medicine
should be chosen.
aSee Appendix Table A1 for detailed overview of the medication that is included in each category.
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2.3 | Outcome assessment
Maternal and obstetric characteristics assessed included age at deliv-
ery, neighbourhood socioeconomic status (SES),18,19 year of delivery,
ethnicity, preconceptional use of medication for chronic conditions
(see Appendix Table A2), parity and GA at birth (ultrasound- or LMP-
based). The proportion of pregnancies during which potentially harm-
ful as well as any medication was used was determined and stratified
by the timing of exposure relative to pregnancy (i.e. preconception,
first trimester, second trimester, third trimester and postpartum). Risk
classification categories were presented separately and combined as
“potentially harmful” (Categories 2–6) and “‘known risk” (Categories
2–5) medication. The medication most often used during pregnancy
was assessed per medication category (2, 3, 4, 5, 6 and none) and the
top 5 presented by pregnancy trimester (excluding reproductive hor-
monal drugs). In order to assess developments over the years, the pro-
portion of pregnancies during which potentially harmful as well as any
medication was used was stratified by the year of delivery. Any medi-
cation included all ATC-coded drugs, in case they were dispensed in
the out-patient pharmacy and not purchased over-the-counter
(including folic acid and vitamin D, although these are nearly always
purchased over-the-counter).
2.4 | Statistical analysis
All analyses were performed using SAS version 9.4 (SAS Institute Inc.,
Cary, NC, USA). Logistic regression models were used to calculate
unadjusted odds ratios (ORs) and 95% confidence intervals (Cis) to
estimate associations between maternal and obstetric characteristics
and use of potentially harmful medication. Missing categories were
created for SES, ethnicity and parity. Trends over time were tested by
Poisson regression at P-value <0.05.
3 | RESULTS
In total, 487 122 pregnancies were selected from the PPRN between
1999 and 2017 for inclusion in the study (Table 2). During 357 226
(73%) of all the pregnancies, women used any medication at least
once. Overall, women used potentially harmful medication during
166 484 (34%) of these pregnancies. This was 43% preconception,
24% during the first trimester, 19% during the second trimester, 16%
during the third trimester and 45% postpartum (Figure 1). The highest
prevalence was observed for medication with unknown risk (Category
6; ranging from 9% to 31%) and the lowest for medication with tera-
togenic effects that require monitoring (Category 4; ranging from
<0.5% to 1%), regardless of the timing relative to pregnancy. Similar
periconceptional patterns were observed for any medication with
overall higher prevalence (preconception: 71%, first trimester: 58%,
second trimester: 55%, third trimester: 53%, postpartum: 80%). Sensi-
tivity analyses in which drug exposure prevalence during these
periods was based on drug dispensings rather than treatment epi-
sodes showed very similar results: all percentage differences in rec-
alculated prevalences were smaller than 0.5% (data not presented).
Table 2 shows that preconceptional use of medication for chronic
conditions was strongly associated with potentially harmful medica-
tion use (OR 3.82, 95% CI 3.77–3.86), particularly antipsychotics and
drugs used in diabetes. The use of potentially harmful medication was
observed to a significantly larger extent among women of non-Dutch
ethnicity compared with Dutch women (OR Moroccan/Turkish: 1.41,
95% CI 1.38–1.44; OR other European/Western: 1.09, 95% CI
1.05–1.12; OR Other: 1.25, 95% CI 1.22–1.28).
An overall declining trend over the years for any medication use
was observed, from 84% in 1999 to 68% in 2017 (Figure 2). However,
no clear long-term linear trend is apparent for the potentially harmful
medication categories presented in this figure. Combining this infor-
mation, the proportion of “potentially harmful medication” relative to
“any medication” increased from 39% in 1999 to about 50% from
2011 onwards (data not presented in figure). Pregnancies during
which women used potentially harmful medication were predomi-
nantly in Category 6 (63%), followed by Category 3 (33%), Category
2 (29%), Category 5 (11%) and Category 4 (1%).
The top five medications used in each category are presented in
Table 3. The table shows that among drugs with pharmacological
effects that require monitoring (Category 2), the nervous system
drugs (psycholeptics and psychoanaleptics) were at the top. A marked
increase for temazepam was observed in the third trimester, which is
used for short-term treatment of insomnia and is one of the preferred
choices during pregnancy. Nitrofurantoin, which should be avoided
only around the due date, was most often used within Category
3, including drugs with pharmacological effects that should be (tempo-
rarily) avoided, followed by ibuprofen (contraindicated in third trimes-
ter), naproxen (contraindicated in third trimester), acetylsalicylic acid
(contraindicated in third trimester at daily dose >80 mg) and
promethazine (should be avoided in last weeks of pregnancy, however
known for its sedating side effect in favour of other sleep medication).
Overall, the prevalence of drugs with teratogenic effects that require
TABLE A2 ATC codes for use of medication for chronic
conditions
Chronic condition ATC
Drugs used in diabetes A10
Corticosteroids, dermatological preparations D07
Corticosteroids for systemic use H02
Thyroid therapy H03
Anti-inflammatory and antirheumatic
products
M01
Antimigraine medication N02C
Antiepileptics N03A
Antipsychotics N05A, excl.
N05AB04
Antidepressants N06A
Antiasthmatics R03
Note: Preconceptional use was defined similar to all other medication clas-
ses assessed (i.e. an active treatment episode within 40 weeks before the
conception date).
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TABLE 2 Maternal and obstetric characteristics of included pregnancies, stratified by use of potentially harmful medication during pregnancy
Characteristic
Study
cohort
Use of potentially harmful
medication (Cat. 2–6)
No use of potentially harmful
medication (Cat. 2–6)
OR (95% CI) use vs.
no use
N = 487 122 N = 166 484 (34%) N = 320 638 (66%)
n (%) n (%) n (%)
Age at delivery (years)
≤20 7837 (2) 2900 (2) 4937 (2) 1.18 (1.13–1.24)
21–30 213 153 (44) 70 742 (42) 142 411 (44) 1 (reference)
31–40 254 949 (52) 87 868 (53) 167 081 (52) 1.06 (1.05–1.07)
≥41 11 183 (2) 4974 (3) 6209 (2) 1.61 (1.55–1.68)
Mean ± SD 31 ± 5 31 ± 5 31 ± 5 1.06 (1.06–1.07)a
SES
Low 171 623 (35) 61 490 (37) 110 133 (34) 1.12 (1.11–1.14)
Normal 151 123 (31) 50 165 (30) 100 958 (31) 1 (reference)
High 162 414 (33) 54 114 (33) 108 300 (34) 1.01 (0.99–1.02)
Unknown 1962 (<0.5) 715 (<0.5) 1247 (<0.5) -
Year of delivery
1999–2003 74 812 (15) 24 833 (15) 49 979 (16) 1 (reference)
2004–2008 134 370 (28) 45 639 (27) 88 731 (28) 1.04 (1.02–1.05)
2009–2013 142 759 (29) 51 685 (31) 91 074 (28) 1.14 (1.12–1.16)
2014–2017 135 181 (28) 44 327 (27) 90 854 (28) 0.98 (0.96–1.00)
Ethnicity
Dutch 388 723 (80) 128 584 (77) 260 139 (81) 1 (reference)
Moroccan/Turkish 35 400 (7) 14 550 (9) 20 850 (7) 1.41 (1.38–1.44)
Other European/Westernb 16 025 (3) 5601 (3) 10 424 (3) 1.09 (1.05–1.12)
Otherc 44 609 (9) 17 036 (10) 27 573 (9) 1.25 (1.22–1.28)
Unknown 2365 (<0.5) 713 (<0.5) 1652 (1) -
Medication for chronic
conditionsd
150 232 (31) 83 418 (50) 66 814 (21) 3.82 (3.77–3.86)
Drugs used in diabetes 2677 (1) 2360 (1) 317 (<0.5) 14.53 (12.92–16.34)
Corticosteroids,
dermatological preparations
47 269 (10) 25 508 (15) 21 761 (7) 2.48 (2.44–2.53)
Corticosteroids for systemic
use
7036 (1) 5004 (3) 2032 (1) 4.86 (4.61–5.12)
Thyroid therapy 8517 (2) 4362 (3) 4155 (1) 2.05 (1.96–2.14)
Anti-inflammatory and
antirheumatic products
70 340 (14) 37 632 (23) 32 708 (10) 2.57 (2.53–2.61)
Antimigraine medication 8730 (2) 6136 (4) 2594 (1) 4.69 (4.48–4.91)
Antiepileptics 2937 (1) 2508 (2) 429 (<0.5) 11.42 (10.30–12.65)
Antipsychotics 3185 (1) 2913 (2) 272 (<0.5) 20.92 (18.48–23.69)
Antidepressants 19 583 (4) 16 563 (10) 3020 (1) 11.62 (11.17–12.08)
Antiasthmatics 24 602 (5) 14 153 (9) 10 449 (3) 2.76 (2.69–2.83)
Parity
0 219 670 (45) 76 845 (46) 142 825 (45) 1 (reference)
1 24 802 (5) 7884 (5) 16 918 (5) 0.87 (0.84–0.89)
2 161 309 (33) 52 764 (32) 108 545 (34) 0.90 (0.89–0.92)
≥3 81 295 (17) 28 975 (17) 52 320 (16) 1.03 (1.01–1.05)
Unknown 46 (<0.5) 16 (<0.5) 30 (<0.5) -
(Continues)
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monitoring (Category 4) was low across all trimesters (≤0.1%). Of
those Category 5 drugs with teratogenic effects that should be (tem-
porarily) avoided, doxycycline (should be avoided in second and third
trimester) was most often used, followed by minocycline (con-
traindicated in second and third trimester), valproic acid (con-
traindicated during pregnancy, unless other epilepsy treatment is
inadequate), acenocoumarol (should be avoided from 6 weeks GA
onwards) and enalapril (contraindicated in second and third trimester).
In Category 6 including drugs with unknown risk, a clear decrease in
prevalence was observed reflecting patients who switched or stopped
nonpreferred treatment. For cabergoline, used to suppress lactation, a
high increase was observed in the third trimester. Among medication
without a category assigned, pregnancy-related drugs were most
apparent. For example, a clear increase was observed in meclozine
use in the first trimester, which is prescribed for nausea and vomiting
in pregnancy. Use of ferrous fumarate also increased over the trimes-
ters, which is recommended for maternal anaemia.
4 | DISCUSSION
This study shows a high prevalence of exposure to potentially harm-
ful medication during pregnancy in the Netherlands from 1999 to
2017. Over all the study years, potentially harmful medication was
TABLE 2 (Continued)
Characteristic
Study
cohort
Use of potentially harmful
medication (Cat. 2–6)
No use of potentially harmful
medication (Cat. 2–6)
OR (95% CI) use vs.
no use
N = 487 122 N = 166 484 (34%) N = 320 638 (66%)
n (%) n (%) n (%)
GA at birth (weeks)
≤24 1875 (<0.5) 803 (<0.5) 1072 (<0.5) 1.48 (1.35–1.62)
25- < 28 1455 (<0.5) 648 (<0.5) 807 (<0.5) 1.58 (1.43–1.76)
28- < 33 5679 (1) 2327 (1) 3352 (1) 1.37 (1.30–1.44)
33- < 37 29 385 (6) 11 702 (7) 17 683 (6) 1.30 (1.27–1.34)
≥37 448 728 (92) 151 004 (91) 297 724 (93) 1 (reference)
Mean ± SD 39.2 ± 2.2 39.0 ± 2.4 39.3 ± 2.1 0.75 (0.75–0.76)a
OR = odds ratio; CI = confidence interval; SD = standard deviation; SES = neighbourhood socioeconomic status; GA = gestational age;
aOR for 5 units change;
bIncluding North American and Canadian;
cCreole, Hindu, Asia and other;
dMedication use for chronic conditions was assessed preconception (see Appendix Table 2 for definitions).
F IGURE 1 Medication use during the
preconception, pregnancy and
postpartum periods categorized
according to the 2016 risk classification
system for drugs in pregnancy of the
DutchTeratology Information Service
Lareb
All trends over time were statistically
significant at P-value <0.05
6 HOUBEN ET AL.
used during approximately one-third of pregnancies, including drugs
with known and unknown risks to a similar extent. Although there
was a declining trend in overall medication use, no such trend was
observed for potentially harmful medication, indicating an increasing
share of potentially harmful medication relative to all medication
used. Most notably, potentially harmful medication use was signifi-
cantly higher among women with preconceptional use of medication
for chronic conditions and women of non-Dutch ethnicity. Exposure
was most common during the first trimester for all risk categories.
Although in particular the use of drugs with known teratogenic
effects dropped most markedly in the second and third trimester,
exposure to harmful medications such as non-steroidal anti-
inflammatory drugs (NSAIDs), tetracyclines or valproic acid remained
common.
The current study findings are in line with those in previous
Dutch studies on medication exposure during pregnancy. Our esti-
mate of overall medication use was somewhat lower than observed
in a study published in 2006 (73% vs. 79%).6 This is probably due
to differences in patient selection (e.g. their restriction to first preg-
nancies), as well as the extension of our study into more recent
years. A recent Dutch, tertiary academic centre study of pregnant
and lactating women showed that 68.2% used prescribed medica-
tion.7 However, next to the difference in study setting, participants
using only vitamin D, folic acid and/or multivitamins during preg-
nancy were classified as nonmedication users, contrary to the cur-
rent study. We observed a decreasing trend for any medication use
over the years. Similar recent studies focusing on Dutch population-
based trends are limited. Increasing multinational trends were
described in two papers published in the last decade, and attributed
to older maternal age and associated pre-existing medical conditions
that require pharmacotherapy.5,20 In addition to international differ-
ences, the study period differed and the main focus was on the
number of medications used (i.e. polypharmacy) rather than the
binomial outcome of medication use applied in this study. Focusing
on potentially harmful medication specifically, other recently
reported rates were somewhat higher than those presented here.7
As well as the different make-up of their study population, they
used a questionnaire design taking into account over-the-counter
drugs. Studies assessing medication use during preconception, preg-
nancy and postpartum periods and classified per risk category are
limited. In a Dutch study from 2006, decreasing exposure to poten-
tially harmful medication was reported from 30% in the first trimes-
ter to 14% in the third trimester, increasing to 45% postpartum.6
This is very similar to the patterns we observed for all risk catego-
ries together. Contrary to the current study, an increase in overall
prescription rates during pregnancy trimesters was observed. This
can be attributed to their exclusion of contraceptive prescriptions,
the main drugs used before pregnancy.21
Our results have important implications for public health. The
unchanged high use of medication with known risks suggests a
potential deficit of risk perception among healthcare providers and
pregnant women. The increased relative share of potentially harmful
medication together with the decline in overall medication use
implies that patients with high-risk conditions requiring pharmaceu-
tical treatment continue their therapy, supported also by the strong
associations with chronic medication use in this study. This is in line
with the abovementioned increase in maternal age and pre-existing
medical conditions (e.g. diabetes) over the years, as recorded in the
F IGURE 2 Trends in medication use during pregnancy, categorized according to 2016 risk classification system for drugs in pregnancy of the
DutchTeratology Information Service Lareb
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annual Perined reports and substantiated in this study cohort.22
Healthcare providers, including pharmacists, have to recognize and
shoulder their responsibility for drug use surveillance among women
of reproductive age. A recent Dutch study has shown that pregnant
women perceived most drugs relatively low in risk and high in bene-
fit. This should be taken into account when counselling them.23 The
TABLE 3 Top 5 medications used during pregnancy trimesters according to 2016 risk classification system for drugs in pregnancy of the
DutchTeratology Information Service Lareb
Medication (ATC)a
Preconception First trimester Second trimester Third trimester
N = 487 122 N = 487 122 N = 487 122 N = 483 799
n (%) n (%; changec) n (%; changed) n (%; changee)
Cat. 2: Pharmacological effects; require monitoring
#1. Temazepam (N05CD07) 6347 (1) 2402 (0.5; −62%) 2016 (0.4; −16%) 5328 (1; +166%)
#2. Oxazepam (N05BA04) 9781 (2) 3999 (0.8; −59%) 2774 (0.6; −31%) 2541 (0.5; −8%)
#3. Paroxetine (N06AB05) 5328 (1) 3756 (0.8; −30%) 2875 (0.6; −23%) 2529 (0.5; −11%)
#4. Betamethasone (D07AC01) 5338 (1) 2566 (0.5; −52%) 1901 (0.4; −26%) 1406 (0.3; −26%)
#5. Prednisolone (H02AB06) 3705 (0.8) 1644 (0.3; −56%) 1570 (0.3; −5%) 1487 (0.3; −5%)
Cat. 3: Pharmacological effects; avoid (temporarily)
#1. Nitrofurantoin (J01XE01) 23 101 (5) 10 851 (2; −53%) 14 904 (3; +37%) 9852 (2; −33%)
#2. Ibuprofen (M01AE01) 25 081 (5) 6784 (1; −73%) 3216 (0.7; −53%) 2344 (0.5; −27%)
#3. Naproxen (M01AE02) 17 088 (4) 4472 (0.9; −74%) 1836 (0.4; −59%) 1358 (0.3; −26%)
#4. Acetylsalicylic acid (B01AC06) 842 (0.2) 2514 (0.5; +199%) 3174 (0.7; +26%) 2878 (0.6; −9%)
#5. Promethazine (R06AD02) 1266 (0.3) 840 (0.2; −34%) 1167 (0.2; +39%) 1416 (0.3; +22%)
Cat. 4: Teratogenic effects; require monitoring
#1. Carbamazepine (N03AF01) 591 (0.1) 485 (<0.1; −18%) 474 (<0.1; −2%) 457 (<0.1; −3%)
#2. Valproic acid (N03AG01) 589 (0.1) 446 (<0.1; −24%) 393 (<0.1; −12%) 367 (<0.1; −6%)
#3. Propylthiouracil (H03BA02) 314 (<0.1) 373 (<0.1; +19%) 393 (<0.1; +5%) 289 (<0.1; −26%)
#4. Lithium (N05AN01) 299 (<0.1) 271 (<0.1; −9%) 242 (<0.1; −11%) 259 (<0.1; +8%)
#5. Thiamazole (H03BB02) 460 (<0.1) 258 (<0.1; −44%) 207 (<0.1; −20%) 139 (<0.1; −32%)
Cat. 5: Teratogenic effects; avoid (temporarily)
#1. Doxycycline (J01AA02) 17 909 (4) 3625 (0.7; −80%) 1704 (0.3; −53%) 1178 (0.2; −30%)
#2. Minocycline (J01AA08) 1651 (0.3) 623 (0.1; −62%) 374 (<0.1; −40%) 315 (<0.1; −15%)
#3. Valproic acid (N03AG01) 589 (0.1) 446 (<0.1; −24%) 393 (<0.1; −12%) 367 (<0.1; −6%)
#4. Acenocoumarol (B01AA07) 510 (0.1) 347 (<0.1; −32%) 351 (<0.1; +1%) 288 (<0.1; −17%)
#5. Enalapril (C09AA02) 391 (<0.1) 258 (<0.1; −34%) 193 (<0.1; −25%) 119 (<0.1; −38%)
Cat. 6: Unknown risk
#1. Desloratadine (R06AX27) 12 018 (2) 4855 (1.0; −60%) 2571 (0.5; −47%) 1721 (0.4; −33%)
#2. Ketoconazole (D01AC08) 7046 (1) 3986 (0.8; −43%) 3367 (0.7; −16%) 2453 (0.5; −27%)
#3. Levocetirizine (R06AE09) 9555 (2) 4382 (0.9; −54%) 2548 (0.5; −42%) 1666 (0.3; −34%)
#4. Mometasone (R01AD09) 7372 (2) 4207 (0.9; −43%) 2773 (0.6; −34%) 1831 (0.4; −34%)
#5. Cabergoline (G02CB03) 1291 (0.3) 448 (<0.1; −65%) 513 (0.1; +15%) 4098 (0.8; +704%)
Medication without category assignedb
#1. Ferrous fumarate (B03AA02) 11 519 (2) 7465 (2; −35%) 24 705 (5; +231%) 45 553 (9; +86%)
#2. Miconazole (G01AF04) 25 417 (5) 15 827 (3; −38%) 27 272 (6; +72%) 28 675 (6; +6%)
#3. Amoxicillin (J01CA04) 23 321 (5) 11 769 (2; −50%) 20 160 (4; +71%) 19 530 (4; −2%)
#4. Meclozine, combinations (R06AE55) 1439 (0.3) 27 419 (6; +1805%) 19 263 (4; −30%) 3140 (0.6; −84%)
#5. Folic acid (B03BB01) 16 747 (3) 22 168 (5; +32%) 19 257 (4; −13%) 9521 (2; −50%)
Note: Top 5 determined during entire pregnancy combining first, second and third trimester;
aExcluding reproductive hormonal drugs (ATC G03);
bAccording to the 2016 risk classification system for drugs in pregnancy of the DutchTeratology Information Service Lareb;
Percentage change in proportion that used medication calculated relative to: cpreconception, dfirst trimester, and esecond trimester.
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higher use among women of non-Dutch ethnicity suggests that
these patients in particular have difficulty obtaining, understanding
and implementing health information as demonstrated also in previ-
ous research.24 Treating physicians rely on available evidence on
risks when making decisions and daily face difficulties balancing
drugs' risks and benefits.25 A high proportion of drugs are labelled
as “unknown risk”, lacking specific recommendations for use during
pregnancy.26 As exposure rates were highest in early pregnancy,
which can be expected as sometimes pregnancy is still unknown,
preconception counselling of the general population would in theory
make women more aware of the risks of certain pharmacological
treatments in relation to pregnancy. This could help to improve pre-
vention of potentially harmful medication use. However, the imple-
mentation of preconception care in European countries is still very
limited.26–28 In order to achieve speedy and scalable benefits to
public health, it was recently suggested that an advocacy coalition
of groups interested in preconception health should be developed
to harness the political will and leadership necessary to turn high-
level policy into effective coordinated action.29
These results highlight the need for an expansion of medication-
risk knowledge and communication by means of targeted preventive
interventions, research and education programmes, so that specific
recommendations can be made for medication use during pregnancy.
Novel insights on the consequences of drug exposure during preg-
nancy should and can be gained, for example from the nearly 20 years
of follow-up data currently available in the PPRN and other registries
such as pREGnant.30 Next to that, drug-centric research would enable
assessment of dose–response relationships and provide insight on
patient-level pregnancy-centred treatment patterns and alternatives
(i.e. individualized care). Based on the current results, NSAIDs, tetra-
cyclines, valproic acid or, more generally, medication for chronic con-
ditions would be eligible for prioritization in such studies. Future
research should focus on the challenge of actually achieving the
desired risk perception, responsibility and activism in the context of
risk management.
This observational study used nearly 20 years of data from a large
population-based cohort, combining drug dispensing and pregnancy
records and was shown to be representative of the Dutch popula-
tion.11 The timing of drug exposure relative to pregnancy staging
could be accurately assessed based on LMP, ultrasound, exact delivery
date, drug dispensing dates and intended duration of use. A limitation
of Perined is that first trimester miscarriages were unable to be
included, thereby potentially underestimating miscarriage-inducing
medication.
A common challenge in using administrative data is defining
drug exposure or compliance. Treatment episodes based on dispens-
ing records can only approximate actual exposure and, particularly
during pregnancy, drugs may be discontinued. Drug exposure could
therefore have been overestimated, although sensitivity analyses
using dispensing dates showed similar exposure rates. Under-
estimated drug exposure is likely because hospital-administered
drugs and over-the-counter drugs sold outside pharmacies were not
captured.
Of importance in this study was the use of a risk classification
system for drugs in pregnancy that did not take into account individu-
alized care in which drug risks are balanced with benefits. Also, the
proportion of drugs with unknown risks was relatively high and there-
fore a statement could only be made on potentially harmful medica-
tion. In addition, risk classifications have evolved and been revised
over time, and we specifically designed our study to use recent
insights. Although some risk classification categories only apply during
specific parts of pregnancy, no distinction was made between preg-
nancy trimesters for the trends in medication use during pregnancy
over time. To put this into perspective, we also determined per-
iconceptional patterns of exposure to risk classification categories.
The risks of medication used in relation to breastfeeding were beyond
the scope of this paper.
Our study shows that the use of potentially harmful medication
was high over the last two decades, especially among ethnic minorities
and women with chronic medical conditions. Although there was a
declining trend over the years in overall medication use, during a
steady one-third of pregnancies women used potentially harmful med-
ication. Our findings highlight the need for an increased sense of
urgency among both healthcare providers and women of reproductive
age regarding the potential risks associated with pharmacological
treatment during pregnancy. In order to be able to make specific rec-
ommendations, medication-risk knowledge needs to be expanded and
readily accessible. Political will and leadership are needed to turn high-
level policy on preconception care into effective coordinated action.
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APPENDIX A
TABLE A1 ATC codes for medication categories according to the 2016 risk classification system for drugs in pregnancy of the Dutch
Teratology Information Service Lareb
Category Name ATC
1. Wide experience; can be used
Medicines used in research or in practice
without showing a raised prevalence of
congenital defects, or (in)direct harmful
effects in the embryo, fetus or newborn.
N.A. (category not included in current study) N.A.
2. Pharmacological effects; require
monitoring
Medicines known or suspected to result in
pharmacological effects in the embryo,
fetus or newborn. The use of these
medicines must be considered carefully.
When used, monitoring for side effects is
needed.
Dexamethasone A01AC02
Epinephrine A01AD01
Atropine A03BA01
Prednisolone A07EA01
Betamethasone A07EA04
Quinidine C01BA01
Lidocaine C01BB01
Propranolol C07AA05
Metoprolol C07AB02
Atenolol C07AB03
Labetalol C07AG01
Nifedipine C08CA05
Betamethasone D07AC01
Desoximetasone D07AC03
Diflucortolone D07AC06
Amcinonide D07AC11
Mometasone D07AC13
Fluticasone D07AC17
Clobetasol D07AD01
Fenoterol G02CA03
Fludrocortisone H02AA02
Betamethasone H02AB01
Dexamethasone H02AB02
Methylprednisolone H02AB04
Prednisolone H02AB06
Prednisone H02AB07
Triamcinolone H02AB08
Hydrocortisone H02AB09
Cortisone H02AB10
Rifampicin J04AB02
Trastuzumab L01XC03
Trastuzumab emtansine L01XC14
Ciclosporin L04AD01
Azathioprine L04AX01
Suxamethonium M03AB01
Atracurium M03AC04
Rocuronium bromide M03AC09
Mivacurium chloride M03AC10
Cisatracurium M03AC11
Enflurane N01AB04
(Continues)
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TABLE A1 (Continued)
Category Name ATC
Isoflurane N01AB06
Desflurane N01AB07
Sevoflurane N01AB08
Thiopental N01AF03
Fentanyl N01AH01
Alfentanil N01AH02
Sufentanil N01AH03
Remifentanil N01AH06
Ketamine N01AX03
Etomidate N01AX07
Propofol N01AX10
Nitrous Oxide N01AX13
Morphine N02AA01
Hydromorphone N02AA03
Nicomorphine N02AA04
Oxycodone N02AA05
Dihydrocodeine N02AA08
Dihydrocodeine, combinations N02AA58
Pethidine N02AB02
Fentanyl N02AB03
Dextromoramide N02AC01
Pentazocine N02AD01
Buprenorphine N02AE01
Dihydrocodeine and Paracetamol N02AJ01
Dihydrocodeine and Acetylsalicylic acid N02AJ02
Dihydrocodeine and other non-opioid analgesics N02AJ03
Tramadol N02AX02
Haloperidol N05AD01
Oxazepam N05BA04
Lorazepam N05BA06
Temazepam N05CD07
Zopiclone N05CF01
Zolpidem N05CF02
Imipramine N06AA02
Clomipramine N06AA04
Amitriptyline N06AA09
Nortriptyline N06AA10
Fluoxetine N06AB03
Citalopram N06AB04
Paroxetine N06AB05
Sertraline N06AB06
Fluvoxamine N06AB08
Escitalopram N06AB10
Bupropion N06AX12
Venlafaxine N06AX16
Buprenorphine N07BC01
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TABLE A1 (Continued)
Category Name ATC
Methadone N07BC02
Fenoterol R03AC04
Salbutamol R03CC02
Fenoterol R03CC04
Theophylline R03DA04
Aminophylline R03DA05
Prednisolone S01BA04
Timolol S01ED01
Betaxolol S01ED02
Levobunolol S01ED03
Carteolol S01ED05
Ciclosporin S01XA18
Diazoxide V03AH01
3. Pharmacological effects; avoid
(temporarily)
Medicines known or suspected to result in
pharmacological effects in the embryo,
fetus or newborn. These medicines should
not be used during this hazardous period;
an alternative medicine should be chosen.
Tetracycline A01AB13
Magnesium silicate A02AA05
Atropine A03BA01
Liquid paraffin A06AA01
Senna glycosides A06AB06
Acetylsalicylic acid B01AC06
Carbasalate calcium B01AC08
Amiodarone C01BD01
Norepinephrine C01CA03
Phenylephrine C01CA06
Ephedrine C01CA26
Indometacin C01EB03
Ibuprofen C01EB16
Hydrochlorothiazide C03AA03
Furosemide C03CA01
Positonen-Iodine D08AG02
Iodine D08AG03
Positonen-Iodine G01AX11
Iodine therapy H03CA
Thiamphenicol J01BA02
Thiamphenicol, combinations J01BA52
Sulfamethoxazole J01EC01
Sulfadiazine J01EC02
Sulfamethoxazole and Trimethoprim J01EE01
Sulfametrole and Trimethoprim J01EE03
Fusidic acid J01XC01
Nitrofurantoin J01XE01
Phenylbutazone M01AA01
Indometacin M01AB01
Proglumetacin M01AB14
Aceclofenac M01AB16
Piroxicam M01AC01
Tenoxicam M01AC02
(Continues)
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TABLE A1 (Continued)
Category Name ATC
Meloxicam M01AC06
Ibuprofen M01AE01
Naproxen M01AE02
Ketoprofen M01AE03
Flurbiprofen M01AE09
Tiaprofenic acid M01AE11
Dexketoprofen M01AE17
Nabumetone M01AX01
Nimesulide M01AX17
Ibuprofen M02AA13
Diclofenac M02AA15
Nimesulide M02AA26
Acetylsalicylic acid N02BA01
Carbasalate calcium N02BA15
Chlorpromazine N05AA01
Ephedrine R01AA03
Pseudoephedrine R01BA02
Flurbiprofen R02AX01
Combinations R05CA10
Promethazine R06AD02
Chloramphenicol S01AA01
Ketorolac S01BC05
Phenylephrine S01FB01
Phenylephrine S01GA05
X-Ray contrast media, iodinated V08A
4. Teratogenic effects; require
monitoring
Medicines known or suspected to cause a
higher prevalence of congenital defects or
other permanent damage or that can
have harmful pharmacological effects in
the embryo, fetus or newborn. Usage
must be considered carefully, and if so,
monitoring for undesirable effects is
needed.
Propylthiouracil H03BA02
Carbimazole H03BB01
Thiamazole H03BB02
Phenobarbital N03AA02
Primidone N03AA03
Phenytoin N03AB02
Carbamazepine N03AF01
Valproic acid N03AG01
Topiramate N03AX11
Lithium N05AN
5. Teratogenic effects; avoid
(temporarily)
Medicines known or suspected to cause a
higher prevalence of congenital defects or
other permanent damage and that can
have harmful pharmacological effects in
the embryo, fetus or infant. These
medicines should not be used during this
hazardous period; an alternative medicine
should be chosen.
Doxycycline A01AB22
Misoprostol A02BB01
Neomycin A07AA01
Nandrolone A14AB01
Warfarin B01AA03
Phenprocoumon B01AA04
Acenocoumarol B01AA07
Captopril C09AA01
Enalapril C09AA02
Lisinopril C09AA03
Perindopril C09AA04
14 HOUBEN ET AL.
TABLE A1 (Continued)
Category Name ATC
Ramipril C09AA05
Quinapril C09AA06
Benazepril C09AA07
Cilazapril C09AA08
Fosinopril C09AA09
Zofenopril C09AA15
Losartan C09CA01
Eprosartan C09CA02
Valsartan C09CA03
Irbesartan C09CA04
Candesartan C09CA06
Telmisartan C09CA07
Olmesartan medoxomil C09CA08
Acitretin D05BB02
Isotretinoin D10BA01
Alitretinoin D11AH04
Nomegestrol and Estradiol G03AA14
Lynestrenol G03AC02
Progesterone G03DA04
Norethisterone G03DC02
Lynestrenol G03DC03
Cyproterone G03HA01
Danazol G03XA01
Demeclocycline J01AA01
Doxycycline J01AA02
Lymecycline J01AA04
Tetracycline J01AA07
Minocycline J01AA08
Tigecycline J01AA12
Tobramycin J01GB01
Gentamicin J01GB03
Kanamycin J01GB04
Neomycin J01GB05
Amikacin J01GB06
Spectinomycin J01XX04
Methotrexate L01BA01
Fluorouracil L01BC02
Megestrol L02AB01
Medroxyprogesterone L02AB02
Tamoxifen L02BA01
Mycophenolic acid L04AA06
Thalidomide L04AX02
Methotrexate L04AX03
Lenalidomide L04AX04
Pomalidomide L04AX06
Penicillamine M01CC01
(Continues)
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TABLE A1 (Continued)
Category Name ATC
Dihydroergotamine N02CA01
Ergotamine N02CA02
Dihydroergotamine, combinations N02CA51
Valproic acid N03AG01
Topiramate N03AX11
Nicotine N07BA01
Quinine P01BC01
6. Unknown risk
Medicines of which the risk for the embryo,
fetus or newborn cannot be determined
because there are insufficient data on
their effect in humans. The use of these
medicines must be considered carefully
and, when possible, another medicine
should be chosen.
In total, 733 substances were included in this category according to the 2016 risk classification system
for drugs in pregnancy of the DutchTeratology Information Service Lareb (examples: ciprofloxacin,
infliximab, ketanserin, midazolam).
Note: Adapted from 2016 risk classification system for drugs in pregnancy of the DutchTeratology Information Service Lareb.17
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